论文部分内容阅读
利用89Y(n,p)89Sr反应在快中子反应堆中制得高比活度89Sr并将其溶于0.01mol/LHCl中,之后加入不同量的SrCl2配制成不同载体含量的溶液;将所得溶液注入正常小鼠体内进行体内分布及急性毒性研究。结果表明:制备的89SrCl2溶液是无菌无热原的澄明溶液,89SrCl2的核纯度>99%,90Sr的含量<1×10-4%,其它伽玛杂质<1×10-2%,89Sr的比活度>185TBq/g,满足医用要求;89SrCl2溶液特异性浓聚于骨,在24h内达到最高,在其它组织中浓聚较少;89SrCl2溶液的载体含量对其在小鼠体内的分布有明显影响,高比活度组(0.5mg/L)在骨中最高浓聚为80.2%(ID%),且7天内骨中的浓聚都显著高于其他组;载体含量对正常小白鼠有较大的毒性,其半致死剂量约为3mg,安全剂量<1mg。
Using 89Y (n, p) 89Sr reaction in a fast reactor to obtain a high specific activity 89Sr and dissolve it in 0.01mol / LHCl, then adding different amounts of SrCl2 to prepare solutions with different carrier content; the resulting solution Into normal mice for in vivo distribution and acute toxicity. The results showed that the prepared 89SrCl2 solution was a clear and pyrogen-free solution. The purity of 89SrCl2 was 99%, the content of 90Sr was less than 1 × 10-4%, the other gamma was less than 1 × 10-2% and 89Sr Specific activity> 185TBq / g, to meet the medical requirements; 89SrCl2 solution specifically concentrated in bone, reached the highest in 24h, less concentrated in other tissues; 89SrCl2 solution of its content in vivo distribution in mice Obviously, the highest concentration of high specific activity group (0.5mg / L) in bone was 80.2% (ID%), and the concentration in bone was significantly higher than other groups within 7 days; Larger toxicity, the semi-lethal dose of about 3mg, safe dose <1mg.